<DOC>
	<DOCNO>NCT02288455</DOCNO>
	<brief_summary>The purpose investigation demonstrate safety efficacy GTU artificial urinary sphincter device restore continence male confirm urinary stress incontinence minimum 12 month primary etiology radical prostatectomy transurethral resection prostate ( TURP ) .</brief_summary>
	<brief_title>Clinical Investigation GT UrologIcal , LLC 's Artificial Urinary Sphincter ( RELIEF II )</brief_title>
	<detailed_description>Prospective , non-randomized multi-center study test safety efficacy GTU artificial urinary sphincter device male urinary incontinence . Up 20 site Europe , Australia &amp; New Zealand A sample size 73 subject estimate provide 80 % power efficacy . Accounting 10 % attrition , 82 subject enrol provide non-missing data 73 subject . First Subject Enrolment : July 2014 Last Subject Enrolment : September 2015 Last Subject Follow-up : September 2016 Study Primary Endpoint Completion : January 2016 Each subject follow approximately 14 month . Study duration approximately 27 month . Subjects evaluate screening , pre-implant , implant , 6 week post implant device activation , 1-month , 2-month , 3-month , 6-month , 12-month post device activation . The Sponsor ( GT Urological , LLC ) work Contract Research Organization ( CRO ) assist investigative site monitor clinical investigation .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>1 . Males &gt; 21 year 2 . Willing/able sign inform consent 3 . Has undergone radical prostatectomy transurethral resection prostate prostate surgery prior 6 month time enrollment 4 . Primary stress urinary incontinence confirm urodynamically dominant form UI 5 . Failed conservative incontinence treatment ( see list ) least 6 month 1 . Pelvic exercise bladder train 2 . Drug Therapy 3 . Biofeedback 4 . Electrical stimulation 5 . Behavioral therapy 6 . Subject severe urinary incontinence define : . One 24hour pad weight test â‰¥300 gm 7 . Max urethral closure pressure &lt; 30 cm H2O 8 . Bladder capacity &gt; 250 ml 9 . Post void residual urine &lt; 50 ml 10 . Abnormal/poor compliance bladder define &lt; 3040cm H2O . 11 . Willing/able comply followup activity 12 . Is appropriate surgical candidate determine investigator 13 . Negative urine culture prior surgery 14 . Cognitive/manual capability operate device 1 . Subjects consider vulnerable 2 . Refuses unable sign inform consent 3 . Can comply study requirement , followup visit test 4 . Currently enrol plan enroll another investigational device drug clinical trial complete investigational study within 2 week 5 . Estimated life span &lt; 5 year 6 . Recent planned surgery within 3 month 12 week implant procedure 7 . Primary urge incontinence , mixed incontinence predominant urgency component , urinary incontinence due complicate bladder outlet obstruction 8 . Has implantation artificial urinary sphincter prosthesis , sling , urogenital implant 9 . Has ProACT device explanted urethra compromise assess investigator 10 . Demonstrated bladder outlet obstruction ( BOO ) measure pressure flow cystometry 11 . Neurogenic bladder dysfunction treatable/controllable pharmacological alternative method 12 . Uncontrolled diabetes mellitus defined persistent blood sugar level recording &gt; 12mmol/l ( 216. mg/dl ) glycosylated hemoglobin ( HbA1C ) &gt; 9 % ( 75mmol/mol ) precede 3 month 13 . Active abscess infection 14 . Bladder neck urethral stricture disease require &gt; 2 regular instrumentation dilation proximal level urethral sheath 15 . Bladder cancer transitional cell carcinoma require regular cystoscopy and/or rapidly progressive prostatic testicular cancer 16 . Needs selfintermittent catheterization 17 . Diagnosed disease preclude subject able recall summarize urinary status 18 . Diagnosed disease medical condition ( e.g. , Parkinson 's ) precluding subject physically capable manipulate device 19 . History bleed diathesis stop usage anticoagulant International Normalized Ratio ( INR ) 1.5 quick value &gt; 70 20 . Uses indwell catheter condom catheter treatment incontinence willing discontinue use study assessment 21 . Abnormal Prostate Screening Antigen ( PSA ) , accord site 's laboratory standard , unless investigation confirm sign local recurrence 22 . Known allergy device material 23 . Active recurrent urinary tract infection ( UTIs ) . Recurrent define &gt; 4 time past year 24 . Urodynamic testing show significant incontinence cause factor stress incontinence 25 . No anatomic abnormality urethra , scrotum penis judge prevent implantation</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>SUI , incontinence , sphincter</keyword>
</DOC>